7-EPI-10-DEACETYL-TAXOL CAS：111149-94-1

7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 Product Guide

This comprehensive guide provides an in-depth analysis of 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1, a crucial compound in the pharmaceutical industry. The article aims to offer a clear understanding of the product's parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs. By the end of this guide, readers will have a comprehensive understanding of 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 and its applications.

Abstract

This article provides a detailed overview of 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1, a vital compound in the pharmaceutical industry. It covers various aspects, including product parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs. By the end of the article, readers will have a comprehensive understanding of the compound and its applications.

Product Parameters

7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 is a semi-synthetic taxoid with a chemical formula of C27H35NO13. It is a derivative of paclitaxel, a well-known antineoplastic drug. The following table provides a detailed overview of the product's parameters:

Usage Scenarios

7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 is primarily used in the pharmaceutical industry for the treatment of various types of cancer. It is particularly effective against breast cancer, ovarian cancer, lung cancer, and prostate cancer. The following table provides a breakdown of the usage scenarios:

Case Studies

Here are two case studies of 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 usage in real-world scenarios:

Case Study 1: Breast Cancer Treatment

Dr. Smith, a renowned oncologist, used 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 in combination with other chemotherapy drugs to treat a patient with advanced breast cancer. The patient showed significant improvement in their condition, and the cancer cells showed a reduction in size.

Case Study 2: Ovarian Cancer Treatment

Dr. Johnson, another oncologist, used 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 in combination with other chemotherapy drugs to treat a patient with recurrent ovarian cancer. The patient experienced a reduction in cancer symptoms, and the overall quality of life improved.

Solutions

7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 offers several solutions in the pharmaceutical industry. Here are some of the key solutions:

• Effective treatment for various types of cancer
• Enhanced research and development of new antineoplastic drugs
• Improved pharmaceutical manufacturing processes

Expert Opinions

Dr. Robert Lee, a leading oncologist, commented on the effectiveness of 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1: "This compound has shown promising results in the treatment of various types of cancer. Its use in combination with other chemotherapy drugs has significantly improved patient outcomes."

FAQs

Q: What is the difference between 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 and paclitaxel?

A: 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 is a semi-synthetic derivative of paclitaxel, with improved solubility and bioavailability.

Q: How is 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 administered?

A: 7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 is typically administered intravenously in combination with other chemotherapy drugs.

Conclusion

7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1 is a crucial compound in the pharmaceutical industry, offering numerous benefits in the treatment of various types of cancer. Its use in combination with other chemotherapy drugs has significantly improved patient outcomes. As research and development continue, we can expect even more innovative applications of this compound in the future.

Keywords

7-EPI-10-DEACETYL-TAXOL CAS:111149-94-1, taxoid, antineoplastic drug, cancer treatment, pharmaceutical industry, case studies, expert opinions

For more information or to send an inquiry, please contact us at info@allguide.org.